Results 11 to 20 of about 37,814 (299)

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration [PDF]

New England Journal of Medicine, 2006
BACKGROUND We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic ...
David M. Brown, Peter K. Kaiser, Mark Michels, G. Soubrane, Jeffrey S. Heier, Robert Y. Kim, Judy P. Sy, Susan Schneider   +7 more
openalex   +2 more sources

Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion [PDF]

BMC Ophthalmology
Objective To compare the effectiveness and safety of three loading doses of bevacizumab and ranibizumab for macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods This retrospective study included 49 patients with BRVO. The patients were
Sibel Coşkun Akdemir, Nurdan Gamze Taşlı   +1 more
doaj   +2 more sources

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration [PDF]

Cost Effectiveness and Resource Allocation, 2008
Background Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain.
Matthews Jane P, Hurley Susan F, Guymer Robyn H   +2 more
doaj   +2 more sources

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment

BMJ Open Ophthalmology, 2023
Topic This systematic review and meta-analysis provides a summary of the efficacy and safety of ranibizumab biosimilars relative to reference ranibizumab anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related ...
Netan Choudhry, Amin Hatamnejad, Rohan Dadak, Samantha Orr, Charles Wykoff   +4 more
doaj   +2 more sources

The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery

Drug Delivery, 2022
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond.
Shrirang V. Ranade, Mark R. Wieland, Tammy Tam, Jennifer C. Rea, Judit Horvath, Aaron R. Hieb, Weitao Jia, Lori Grace, Giulio Barteselli, Jay M. Stewart   +9 more
doaj   +2 more sources

Treatment of age-related macular degeneration: focus on ranibizumab

Clinical Ophthalmology, 2008
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A ...
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter Szurman   +4 more
doaj   +3 more sources

The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients

Scientific Reports, 2021
The ZIPANGU study assessed the efficacy and safety of ranibizumab as a one loading dose + pro re nata (one + PRN) regimen with/without focal/grid laser among treatment-naïve patients suffering from macular edema (ME) following branch retinal vein ...
Toshinori Murata, Mineo Kondo, Makoto Inoue, Shintaro Nakao, Rie Osaka, Chieko Shiragami, Kenji Sogawa, Akikazu Mochizuki, Rumiko Shiraga, Yohei Ohashi, Takeumi Kaneko, Chikatapu Chandrasekhar, Akitaka Tsujikawa, Motohiro Kamei   +13 more
doaj   +2 more sources

Role of ranibizumab in management of macular degeneration

Indian Journal of Ophthalmology, 2007
Age-related macular degeneration (AMD) is one of the most common causes of severe vision loss in the western world. Both animal and human studies have established that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of this process.
Rishi P Singh, Peter K. Kaiser
openaire   +4 more sources

Ranibizumab for the treatment of diabetic retinopathy

Expert Opinion on Biological Therapy, 2021
Introduction: Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus and the leading cause of blindness in young adults. Prior to anti-vascular endothelial growth factor (anti-VEGF) agents, the treatment of DR was based on control of systemic factors and laser photocoagulation. Over the past decade, the use of anti-
I. Chatziralli
openaire   +5 more sources

Ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade [PDF]

, 2009
PURPOSE: To investigate the efficacy of vascular endothelial growth factor-specific (VEGF) monoclonal antibodies in the treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) that does not extend beneath the foveal ...
Amaro, Miguel Hage, Roller, Aaron Brock
core   +5 more sources